<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01446913</url>
  </required_header>
  <id_info>
    <org_study_id>1101007811</org_study_id>
    <secondary_id>U34HL105285-01</secondary_id>
    <nct_id>NCT01446913</nct_id>
  </id_info>
  <brief_title>Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure</brief_title>
  <acronym>SleepTight</acronym>
  <official_title>Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to develop a novel study design to safely and ethically conduct a&#xD;
      long-term randomized controlled trial among patients at high risk for both sleep apnea and&#xD;
      cardiovascular events that will examine whether effective positive airway pressure(PAP)&#xD;
      therapy reduces cardiovascular risk. Patients with transient ischemic attack(TIA) or stroke&#xD;
      have a high prevalence of sleep apnea(60-80%), and they are at high risk of cardiovascular&#xD;
      events(myocardial infarction, congestive heart failure, recurrent stroke, and cardiovascular&#xD;
      death)in the first year post event, despite current prevent strategies. Therefore, the&#xD;
      treatment of sleep apnea may represent a novel therapeutic target to reduce cardiovascular&#xD;
      outcomes in this high risk population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed study is a randomized controlled trial among patients with transient ischemic&#xD;
      attack (TIA) and minor stroke, comparing strategies for the diagnosis and treatment of sleep&#xD;
      apnea with usual care over 6-12 months at 2 sites (Yale University School of Medicine and&#xD;
      Indiana University School of Medicine). Patients with TIA and minor stroke will be randomly&#xD;
      assigned to either usual care or a diagnosis and treatment approach that includes ambulatory&#xD;
      polysomnography and initiation of autotitrating CPAP for sleep apnea in a 1:2&#xD;
      (control:intervention) randomization scheme. Intervention patients with sleep apnea will&#xD;
      receive either a standard CPAP treatment intervention or an enhanced protocol designed to&#xD;
      increase long-term CPAP adherence. The primary outcomes will include: (a) the impact of CPAP&#xD;
      on pathophysiologic markers in the following domains of cardiovascular risk: inflammation&#xD;
      (CRP, Il-6), heightened sympathetic activity/parasympathetic withdrawal (plasma&#xD;
      catecholamines and heart rate variability (HRV)), insulin resistance (HOMA-IR, HbA1C),&#xD;
      endothelial injury (flow mediated vasodilation), and atherosclerosis (carotid intima-media&#xD;
      thickness); and (b) long-term (6-12 month) CPAP adherence.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HOMA IR Change From Baseline</measure>
    <time_frame>Baseline and up to 12 months</time_frame>
    <description>The homeostasis model assessment-estimated insulin resistance (HOMA-IR). HOMA IR change is one of the measures used to assess cardiovascular risk. HOMA-IR Index (measured by calculating - fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5.). The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CRP Change From Baseline</measure>
    <time_frame>Baseline and up to 12 months</time_frame>
    <description>C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood. CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation. CRP is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-6 Change From Baseline</measure>
    <time_frame>Baseline and up to 12 months</time_frame>
    <description>IL-6 is a type of protein known as a cytokine, produced by cells of the immune system in response to an infection. IL-6 test results measure the amount of IL-6 circulating in the blood and are used as one sign of systemic inflammation. Il-6 is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Catecholamine Change From Baseline</measure>
    <time_frame>Baseline and up to 12 months</time_frame>
    <description>Catecholamine testing measures the amounts of catecholamines which are a group of similar substances/hormones released into the blood in response to physical or emotional stress. The primary catecholamines are dopamine, epinephrine (adrenaline), and norepinephrine. Catecholamine is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate Variability Change From Baseline</measure>
    <time_frame>Baseline and up to 12 months</time_frame>
    <description>Heart rate variability (HRV) is the constant variation in milliseconds between heartbeats. HRV is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>24-H Systolic Blood Pressure Mean Change From Baseline</measure>
    <time_frame>Baseline and up to 12 months</time_frame>
    <description>24-H Systolic Blood Pressure is one of the measures used to assess cardiovascular risk- this was assessed multiple times and averaged across a in 24 hour time period. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow-mediated Vasodilation Mean Change From Baseline</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
    <description>Flow-mediated vasodilation is performed when the brachial artery diameter is measured (in mm) during three conditions; baseline (after at least 10 min supine rest), during reactive hyperaemia (induced by inflation to 250 mmHg and then deflation of a sphygmomanometer cuff around the forearm) and finally after the administration of sublingual nitroglycerin. A linear array, high resolution ultrasound transducer is used to provide B-mode images of the target vessel, proximal to the forearm cuff. Flow-mediated vasodilation is one of the measures used to assess cardiovascular risk and the mean of the change in the multiple measurements was used at each time point. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carotid Intima-Medial Thickness Mean Change From Baseline</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
    <description>Carotid Intima-Medial Thickness are measurements of the mean values of Intima-media thickness (IMT) of carotid arteries. Caroid Intima-Medial Thickness mean change is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CPAP Adherence Rates Change From Baseline</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
    <description>CPAP adherence rates were calculated as hours of CPAP use per night. The change from baseline up until the final measurement (up to 12 months) was assessed. The Respironics M-series (now System One, Phillips Respironics, North Ryde, Australia) produced a record of the patient adherence (hours of use per night) throughout the duration of the follow up period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HOMA IR Change From Baseline With CPAP Use</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
    <description>The homeostasis model assessment-estimated insulin resistance (HOMA-IR). HOMA IR change is one of the measures used to assess cardiovascular risk. HOMA-IR Index (measured by calculating - fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5.) To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP Change From Baseline With CPAP Use</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
    <description>C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood. CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation. CRP is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-6 Change From Baseline With CPAP Use</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
    <description>IL-6 is a type of protein known as a cytokine, produced by cells of the immune system in response to an infection. IL-6 test results measure the amount of IL-6 circulating in the blood and are used as one sign of systemic inflammation. IL-6 is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catecholamine Change From Baseline With CPAP Use</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
    <description>Catecholamine testing measures the amounts of catecholamines which are a group of similar substances/hormones released into the blood in response to physical or emotional stress. The primary catecholamines are dopamine, epinephrine (adrenaline), and norepinephrine. Catecholamines change is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Variability Change From Baseline With CPAP Use</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
    <description>Heart rate variability (HRV) is the constant variation in milliseconds between heartbeats. HRV is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24-H Mean Systolic Blood Pressure Change From Baseline With CPAP Use</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
    <description>24-H Mean Systolic Blood Pressure change is one of the measures used to assess cardiovascular risk- this was assessed multiple times and averaged across a in 24 hour time period. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flow-mediated Vasodilation Mean Change From Baseline With CPAP Use</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
    <description>Flow-mediated vasodilation is performed when the brachial artery diameter is measured (in mm) during three conditions; baseline (after at least 10 min supine rest), during reactive hyperaemia (induced by inflation to 250 mmHg and then deflation of a sphygmomanometer cuff around the forearm) and finally after the administration of sublingual nitroglycerin. A linear array, high resolution ultrasound transducer is used to provide B-mode images of the target vessel, proximal to the forearm cuff. Flow-mediated vasodilation is one of the measures used to assess cardiovascular risk and the mean of the change in the multiple measurements was used at each time point. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid Intima-Medial Thickness Change From Baseline With CPAP Use Change</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
    <description>Carotid Intima-Medial Thickness are measurements of the mean values of Intima-media thickness (IMT) of carotid arteries. Caroid Intima-Medial Thickness change is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed. The carotid intimal thickness measurement was obtained by averaging the distance between the lumen-intima interface and the media-adventitia interface obtained from 5 contiguous sites 1 mm apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication-adjusted 24-H SBP Change From Baseline</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
    <description>Change in medication-adjusted 24-hour SBP, which is calculated as [mean 24-hour SBP in mmHg] + [patient's DDD Ã— (8.0 mmHg), was assessed between CPAP adherence groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">255</enrollment>
  <condition>Transient Ischemic Attack</condition>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>Standard Intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enhanced CPAP intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group usual care after TIA/stroke and a sleep study at the end of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard CPAP Intervention</intervention_name>
    <arm_group_label>Standard Intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Enhanced CPAP Intervention</intervention_name>
    <arm_group_label>Enhanced CPAP intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years and older&#xD;
&#xD;
          -  TIA or ischemic stroke&#xD;
&#xD;
          -  within 1 week of neurological symptom onset&#xD;
&#xD;
          -  brain imaging within 24 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  known to have sleep apnea&#xD;
&#xD;
          -  suspected sleep disorder other than sleep apnea&#xD;
&#xD;
          -  hospice patients or patients receiving comfort only measures&#xD;
&#xD;
          -  patients unable to use a nasal or face mask&#xD;
&#xD;
          -  patients who require mechanical ventilation&#xD;
&#xD;
          -  Non English language patients&#xD;
&#xD;
          -  inability to provide informed consent&#xD;
&#xD;
          -  active suicidal ideation&#xD;
&#xD;
          -  live outside the recruitment area&#xD;
&#xD;
          -  provider does not allow researcher to contact patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Yaggi, MD,MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dawn M Bravata, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Koo BB, Bravata DM, Tobias LA, Mackey JS, Miech EJ, Matthias MS, Stahl SM, Sico JJ, Vaz Fragoso CA, Williams LS, Lampert R, Qin L, Yaggi HK. Observational Study of Obstructive Sleep Apnea in Wake-Up Stroke: The SLEEP TIGHT Study. Cerebrovasc Dis. 2016;41(5-6):233-41. doi: 10.1159/000440736. Epub 2016 Jan 27.</citation>
    <PMID>26811929</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 3, 2011</study_first_submitted>
  <study_first_submitted_qc>October 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2011</study_first_posted>
  <results_first_submitted>April 13, 2017</results_first_submitted>
  <results_first_submitted_qc>October 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 18, 2020</results_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sleep Apnea</keyword>
  <keyword>CPAP adherence</keyword>
  <keyword>behavioral adherence</keyword>
  <keyword>stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Resource sharing plan In compliance NIH recommendations, we affirm our commitment to share our final research data in a timely fashion for this proposed study with the scientific community. We intend this to occur no later than the time of acceptance for publication of the main findings from the final dataset. We will share all data from the funded research that can be shared without compromising individual subjects' rights and privacy, regardless of whether the data have been used for publication.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Three patients withdrew prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Intervention Group</title>
          <description>This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.&#xD;
Standard CPAP Intervention</description>
        </group>
        <group group_id="P2">
          <title>Enhanced CPAP Intervention</title>
          <description>This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.&#xD;
Enhanced CPAP Intervention</description>
        </group>
        <group group_id="P3">
          <title>Usual Care</title>
          <description>This group usual care after TIA/stroke and a sleep study at the end of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="82"/>
                <participants group_id="P3" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients With Sleep Study</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients With Sleep Apnea</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Significant illness</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Intervention Group</title>
          <description>This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.&#xD;
Standard CPAP Intervention</description>
        </group>
        <group group_id="B2">
          <title>Enhanced CPAP Intervention</title>
          <description>This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.&#xD;
Enhanced CPAP Intervention</description>
        </group>
        <group group_id="B3">
          <title>Usual Care</title>
          <description>This group usual care after TIA/stroke and a sleep study at the end of the study.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="84"/>
            <count group_id="B4" value="252"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="180"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" spread="12.5"/>
                    <measurement group_id="B2" value="61.3" spread="12.8"/>
                    <measurement group_id="B3" value="60.3" spread="12.5"/>
                    <measurement group_id="B4" value="60.5" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="121"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HOMA IR Change From Baseline</title>
        <description>The homeostasis model assessment-estimated insulin resistance (HOMA-IR). HOMA IR change is one of the measures used to assess cardiovascular risk. HOMA-IR Index (measured by calculating - fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5.). The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline and up to 12 months</time_frame>
        <population>Intention to treat analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Intervention Group</title>
            <description>This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.&#xD;
Standard CPAP Intervention</description>
          </group>
          <group group_id="O2">
            <title>Enhanced CPAP Intervention</title>
            <description>This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.&#xD;
Enhanced CPAP Intervention</description>
          </group>
          <group group_id="O3">
            <title>Usual Care</title>
            <description>This group usual care after TIA/stroke and a sleep study at the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>HOMA IR Change From Baseline</title>
          <description>The homeostasis model assessment-estimated insulin resistance (HOMA-IR). HOMA IR change is one of the measures used to assess cardiovascular risk. HOMA-IR Index (measured by calculating - fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5.). The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>Intention to treat analysis population.</population>
          <units>HOMA-IR Index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="3.0"/>
                    <measurement group_id="O2" value="4.0" spread="12.7"/>
                    <measurement group_id="O3" value="4.1" spread="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CRP Change From Baseline</title>
        <description>C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood. CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation. CRP is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline and up to 12 months</time_frame>
        <population>Intention to treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Intervention Group</title>
            <description>This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.&#xD;
Standard CPAP Intervention</description>
          </group>
          <group group_id="O2">
            <title>Enhanced CPAP Intervention</title>
            <description>This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.&#xD;
Enhanced CPAP Intervention</description>
          </group>
          <group group_id="O3">
            <title>Usual Care</title>
            <description>This group usual care after TIA/stroke and a sleep study at the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Change From Baseline</title>
          <description>C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood. CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation. CRP is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>Intention to treat analysis.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="14.4"/>
                    <measurement group_id="O2" value="0.9" spread="10.2"/>
                    <measurement group_id="O3" value="-3.0" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IL-6 Change From Baseline</title>
        <description>IL-6 is a type of protein known as a cytokine, produced by cells of the immune system in response to an infection. IL-6 test results measure the amount of IL-6 circulating in the blood and are used as one sign of systemic inflammation. Il-6 is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline and up to 12 months</time_frame>
        <population>Intention to treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Intervention Group</title>
            <description>This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.&#xD;
Standard CPAP Intervention</description>
          </group>
          <group group_id="O2">
            <title>Enhanced CPAP Intervention</title>
            <description>This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.&#xD;
Enhanced CPAP Intervention</description>
          </group>
          <group group_id="O3">
            <title>Usual Care</title>
            <description>This group usual care after TIA/stroke and a sleep study at the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>IL-6 Change From Baseline</title>
          <description>IL-6 is a type of protein known as a cytokine, produced by cells of the immune system in response to an infection. IL-6 test results measure the amount of IL-6 circulating in the blood and are used as one sign of systemic inflammation. Il-6 is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>Intention to treat analysis.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="11"/>
                    <measurement group_id="O2" value="1.8" spread="40.6"/>
                    <measurement group_id="O3" value="-0.7" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Catecholamine Change From Baseline</title>
        <description>Catecholamine testing measures the amounts of catecholamines which are a group of similar substances/hormones released into the blood in response to physical or emotional stress. The primary catecholamines are dopamine, epinephrine (adrenaline), and norepinephrine. Catecholamine is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline and up to 12 months</time_frame>
        <population>Intention to treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Intervention Group</title>
            <description>This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.&#xD;
Standard CPAP Intervention</description>
          </group>
          <group group_id="O2">
            <title>Enhanced CPAP Intervention</title>
            <description>This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.&#xD;
Enhanced CPAP Intervention</description>
          </group>
          <group group_id="O3">
            <title>Usual Care</title>
            <description>This group usual care after TIA/stroke and a sleep study at the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Catecholamine Change From Baseline</title>
          <description>Catecholamine testing measures the amounts of catecholamines which are a group of similar substances/hormones released into the blood in response to physical or emotional stress. The primary catecholamines are dopamine, epinephrine (adrenaline), and norepinephrine. Catecholamine is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>Intention to treat analysis.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192.4" spread="385.0"/>
                    <measurement group_id="O2" value="5.8" spread="259.6"/>
                    <measurement group_id="O3" value="89.0" spread="231.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Heart Rate Variability Change From Baseline</title>
        <description>Heart rate variability (HRV) is the constant variation in milliseconds between heartbeats. HRV is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline and up to 12 months</time_frame>
        <population>Intention to treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Intervention Group</title>
            <description>This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.&#xD;
Standard CPAP Intervention</description>
          </group>
          <group group_id="O2">
            <title>Enhanced CPAP Intervention</title>
            <description>This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.&#xD;
Enhanced CPAP Intervention</description>
          </group>
          <group group_id="O3">
            <title>Usual Care</title>
            <description>This group usual care after TIA/stroke and a sleep study at the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Variability Change From Baseline</title>
          <description>Heart rate variability (HRV) is the constant variation in milliseconds between heartbeats. HRV is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>Intention to treat analysis.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="20.0"/>
                    <measurement group_id="O2" value="5.0" spread="30.5"/>
                    <measurement group_id="O3" value="-1.5" spread="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>24-H Systolic Blood Pressure Mean Change From Baseline</title>
        <description>24-H Systolic Blood Pressure is one of the measures used to assess cardiovascular risk- this was assessed multiple times and averaged across a in 24 hour time period. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline and up to 12 months</time_frame>
        <population>Intention to treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Intervention Group</title>
            <description>This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.&#xD;
Standard CPAP Intervention</description>
          </group>
          <group group_id="O2">
            <title>Enhanced CPAP Intervention</title>
            <description>This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.&#xD;
Enhanced CPAP Intervention</description>
          </group>
          <group group_id="O3">
            <title>Usual Care</title>
            <description>This group usual care after TIA/stroke and a sleep study at the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>24-H Systolic Blood Pressure Mean Change From Baseline</title>
          <description>24-H Systolic Blood Pressure is one of the measures used to assess cardiovascular risk- this was assessed multiple times and averaged across a in 24 hour time period. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>Intention to treat analysis.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="12.8"/>
                    <measurement group_id="O2" value="-1.2" spread="12.5"/>
                    <measurement group_id="O3" value="5.9" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Flow-mediated Vasodilation Mean Change From Baseline</title>
        <description>Flow-mediated vasodilation is performed when the brachial artery diameter is measured (in mm) during three conditions; baseline (after at least 10 min supine rest), during reactive hyperaemia (induced by inflation to 250 mmHg and then deflation of a sphygmomanometer cuff around the forearm) and finally after the administration of sublingual nitroglycerin. A linear array, high resolution ultrasound transducer is used to provide B-mode images of the target vessel, proximal to the forearm cuff. Flow-mediated vasodilation is one of the measures used to assess cardiovascular risk and the mean of the change in the multiple measurements was used at each time point. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline to up to 12 months</time_frame>
        <population>Intention to treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Intervention Group</title>
            <description>This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.&#xD;
Standard CPAP Intervention</description>
          </group>
          <group group_id="O2">
            <title>Enhanced CPAP Intervention</title>
            <description>This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.&#xD;
Enhanced CPAP Intervention</description>
          </group>
          <group group_id="O3">
            <title>Usual Care</title>
            <description>This group usual care after TIA/stroke and a sleep study at the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Flow-mediated Vasodilation Mean Change From Baseline</title>
          <description>Flow-mediated vasodilation is performed when the brachial artery diameter is measured (in mm) during three conditions; baseline (after at least 10 min supine rest), during reactive hyperaemia (induced by inflation to 250 mmHg and then deflation of a sphygmomanometer cuff around the forearm) and finally after the administration of sublingual nitroglycerin. A linear array, high resolution ultrasound transducer is used to provide B-mode images of the target vessel, proximal to the forearm cuff. Flow-mediated vasodilation is one of the measures used to assess cardiovascular risk and the mean of the change in the multiple measurements was used at each time point. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>Intention to treat analysis.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="3.0"/>
                    <measurement group_id="O2" value="0.1" spread="2.2"/>
                    <measurement group_id="O3" value="-0.3" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Carotid Intima-Medial Thickness Mean Change From Baseline</title>
        <description>Carotid Intima-Medial Thickness are measurements of the mean values of Intima-media thickness (IMT) of carotid arteries. Caroid Intima-Medial Thickness mean change is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline to up to 12 months</time_frame>
        <population>Intention to treat analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Intervention Group</title>
            <description>This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.&#xD;
Standard CPAP Intervention</description>
          </group>
          <group group_id="O2">
            <title>Enhanced CPAP Intervention</title>
            <description>This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.&#xD;
Enhanced CPAP Intervention</description>
          </group>
          <group group_id="O3">
            <title>Usual Care</title>
            <description>This group usual care after TIA/stroke and a sleep study at the end of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Carotid Intima-Medial Thickness Mean Change From Baseline</title>
          <description>Carotid Intima-Medial Thickness are measurements of the mean values of Intima-media thickness (IMT) of carotid arteries. Caroid Intima-Medial Thickness mean change is one of the measures used to assess cardiovascular risk. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>Intention to treat analysis.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                    <measurement group_id="O3" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>CPAP Adherence Rates Change From Baseline</title>
        <description>CPAP adherence rates were calculated as hours of CPAP use per night. The change from baseline up until the final measurement (up to 12 months) was assessed. The Respironics M-series (now System One, Phillips Respironics, North Ryde, Australia) produced a record of the patient adherence (hours of use per night) throughout the duration of the follow up period.</description>
        <time_frame>Baseline to up to 12 months</time_frame>
        <population>The analysis population is a subset of patients in the standard and enhanced intervention arms that had a diagnosis of sleep apnea.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard</title>
            <description>Standard Intervention patients with a diagnosis of sleep apnea.</description>
          </group>
          <group group_id="O2">
            <title>Enhanced</title>
            <description>Enhanced Intervention patients with a diagnosis of sleep apnea.</description>
          </group>
        </group_list>
        <measure>
          <title>CPAP Adherence Rates Change From Baseline</title>
          <description>CPAP adherence rates were calculated as hours of CPAP use per night. The change from baseline up until the final measurement (up to 12 months) was assessed. The Respironics M-series (now System One, Phillips Respironics, North Ryde, Australia) produced a record of the patient adherence (hours of use per night) throughout the duration of the follow up period.</description>
          <population>The analysis population is a subset of patients in the standard and enhanced intervention arms that had a diagnosis of sleep apnea.</population>
          <units>Hours per night</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="2.1"/>
                    <measurement group_id="O2" value="4.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HOMA IR Change From Baseline With CPAP Use</title>
        <description>The homeostasis model assessment-estimated insulin resistance (HOMA-IR). HOMA IR change is one of the measures used to assess cardiovascular risk. HOMA-IR Index (measured by calculating - fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5.) To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline to up to 12 months</time_frame>
        <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
        <group_list>
          <group group_id="O1">
            <title>No CPAP Use</title>
            <description>Intervention and control patients with none/poor CPAP use</description>
          </group>
          <group group_id="O2">
            <title>Some CPAP Use</title>
            <description>Intervention patients with some CPAP (less than 4 hours per night)</description>
          </group>
          <group group_id="O3">
            <title>Good CPAP Use</title>
            <description>Intervention patients with good CPAP use (&gt;=4 hours per night)</description>
          </group>
        </group_list>
        <measure>
          <title>HOMA IR Change From Baseline With CPAP Use</title>
          <description>The homeostasis model assessment-estimated insulin resistance (HOMA-IR). HOMA IR change is one of the measures used to assess cardiovascular risk. HOMA-IR Index (measured by calculating - fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5.) To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
          <units>HOMA-IR Index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="1.0"/>
                    <measurement group_id="O2" value="2.4" spread="12.0"/>
                    <measurement group_id="O3" value="3.3" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CRP Change From Baseline With CPAP Use</title>
        <description>C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood. CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation. CRP is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline to up to 12 months</time_frame>
        <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
        <group_list>
          <group group_id="O1">
            <title>No CPAP Use</title>
            <description>Intervention and control patients with none/poor CPAP use.</description>
          </group>
          <group group_id="O2">
            <title>Some CPAP Use</title>
            <description>Intervention patients with some CPAP (less than 4 hours per night)</description>
          </group>
          <group group_id="O3">
            <title>Good CPAP Use</title>
            <description>Intervention patients with good CPAP use (&gt;=4 hours per night)</description>
          </group>
        </group_list>
        <measure>
          <title>CRP Change From Baseline With CPAP Use</title>
          <description>C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood. CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation. CRP is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="14.4"/>
                    <measurement group_id="O2" value="0.9" spread="10.2"/>
                    <measurement group_id="O3" value="-3.0" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IL-6 Change From Baseline With CPAP Use</title>
        <description>IL-6 is a type of protein known as a cytokine, produced by cells of the immune system in response to an infection. IL-6 test results measure the amount of IL-6 circulating in the blood and are used as one sign of systemic inflammation. IL-6 is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline to up to 12 months</time_frame>
        <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
        <group_list>
          <group group_id="O1">
            <title>No CPAP Use</title>
            <description>Intervention and control patients with none/poor CPAP use</description>
          </group>
          <group group_id="O2">
            <title>Some CPAP Use</title>
            <description>Intervention patients with some CPAP (less than 4 hours per night)</description>
          </group>
          <group group_id="O3">
            <title>Good CPAP Use</title>
            <description>Intervention patients with good CPAP use (&gt;=4 hours per night)</description>
          </group>
        </group_list>
        <measure>
          <title>IL-6 Change From Baseline With CPAP Use</title>
          <description>IL-6 is a type of protein known as a cytokine, produced by cells of the immune system in response to an infection. IL-6 test results measure the amount of IL-6 circulating in the blood and are used as one sign of systemic inflammation. IL-6 is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="27.3"/>
                    <measurement group_id="O2" value="3.3" spread="11.5"/>
                    <measurement group_id="O3" value="11.9" spread="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Catecholamine Change From Baseline With CPAP Use</title>
        <description>Catecholamine testing measures the amounts of catecholamines which are a group of similar substances/hormones released into the blood in response to physical or emotional stress. The primary catecholamines are dopamine, epinephrine (adrenaline), and norepinephrine. Catecholamines change is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline to up to 12 months</time_frame>
        <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
        <group_list>
          <group group_id="O1">
            <title>No CPAP Use</title>
            <description>Intervention and control patients with none/poor CPAP use</description>
          </group>
          <group group_id="O2">
            <title>Some CPAP Use</title>
            <description>Intervention patients with some CPAP (less than 4 hours per night)</description>
          </group>
          <group group_id="O3">
            <title>Good CPAP Use</title>
            <description>Intervention patients with good CPAP use (&gt;=4 hours per night)</description>
          </group>
        </group_list>
        <measure>
          <title>Catecholamine Change From Baseline With CPAP Use</title>
          <description>Catecholamine testing measures the amounts of catecholamines which are a group of similar substances/hormones released into the blood in response to physical or emotional stress. The primary catecholamines are dopamine, epinephrine (adrenaline), and norepinephrine. Catecholamines change is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" spread="245.5"/>
                    <measurement group_id="O2" value="-27.8" spread="288.2"/>
                    <measurement group_id="O3" value="184" spread="436.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate Variability Change From Baseline With CPAP Use</title>
        <description>Heart rate variability (HRV) is the constant variation in milliseconds between heartbeats. HRV is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline to up to 12 months</time_frame>
        <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
        <group_list>
          <group group_id="O1">
            <title>No CPAP Use</title>
            <description>Intervention and control patients with none/poor CPAP use</description>
          </group>
          <group group_id="O2">
            <title>Some CPAP Use</title>
            <description>Intervention patients with some CPAP (less than 4 hours per night)</description>
          </group>
          <group group_id="O3">
            <title>Good CPAP Use</title>
            <description>Intervention patients with good CPAP use (&gt;=4 hours per night)</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Variability Change From Baseline With CPAP Use</title>
          <description>Heart rate variability (HRV) is the constant variation in milliseconds between heartbeats. HRV is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
          <units>milliseconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="18.9"/>
                    <measurement group_id="O2" value="-5.4" spread="24.8"/>
                    <measurement group_id="O3" value="5.3" spread="33.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>24-H Mean Systolic Blood Pressure Change From Baseline With CPAP Use</title>
        <description>24-H Mean Systolic Blood Pressure change is one of the measures used to assess cardiovascular risk- this was assessed multiple times and averaged across a in 24 hour time period. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline to up to 12 months</time_frame>
        <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
        <group_list>
          <group group_id="O1">
            <title>No CPAP Use</title>
            <description>Intervention and control patients with none/poor CPAP use</description>
          </group>
          <group group_id="O2">
            <title>Some CPAP Use</title>
            <description>Intervention patients with some CPAP (less than 4 hours per night)</description>
          </group>
          <group group_id="O3">
            <title>Good CPAP Use</title>
            <description>Intervention patients with good CPAP use (&gt;=4 hours per night)</description>
          </group>
        </group_list>
        <measure>
          <title>24-H Mean Systolic Blood Pressure Change From Baseline With CPAP Use</title>
          <description>24-H Mean Systolic Blood Pressure change is one of the measures used to assess cardiovascular risk- this was assessed multiple times and averaged across a in 24 hour time period. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="11.1"/>
                    <measurement group_id="O2" value="-4.9" spread="15.0"/>
                    <measurement group_id="O3" value="0.1" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Flow-mediated Vasodilation Mean Change From Baseline With CPAP Use</title>
        <description>Flow-mediated vasodilation is performed when the brachial artery diameter is measured (in mm) during three conditions; baseline (after at least 10 min supine rest), during reactive hyperaemia (induced by inflation to 250 mmHg and then deflation of a sphygmomanometer cuff around the forearm) and finally after the administration of sublingual nitroglycerin. A linear array, high resolution ultrasound transducer is used to provide B-mode images of the target vessel, proximal to the forearm cuff. Flow-mediated vasodilation is one of the measures used to assess cardiovascular risk and the mean of the change in the multiple measurements was used at each time point. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline to up to 12 months</time_frame>
        <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
        <group_list>
          <group group_id="O1">
            <title>No CPAP Use</title>
            <description>Intervention and control patients with none/poor CPAP use</description>
          </group>
          <group group_id="O2">
            <title>Some CPAP Use</title>
            <description>Intervention patients with some CPAP (less than 4 hours per night)</description>
          </group>
          <group group_id="O3">
            <title>Good CPAP Use</title>
            <description>Intervention patients with good CPAP use (&gt;=4 hours per night)</description>
          </group>
        </group_list>
        <measure>
          <title>Flow-mediated Vasodilation Mean Change From Baseline With CPAP Use</title>
          <description>Flow-mediated vasodilation is performed when the brachial artery diameter is measured (in mm) during three conditions; baseline (after at least 10 min supine rest), during reactive hyperaemia (induced by inflation to 250 mmHg and then deflation of a sphygmomanometer cuff around the forearm) and finally after the administration of sublingual nitroglycerin. A linear array, high resolution ultrasound transducer is used to provide B-mode images of the target vessel, proximal to the forearm cuff. Flow-mediated vasodilation is one of the measures used to assess cardiovascular risk and the mean of the change in the multiple measurements was used at each time point. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="3.2"/>
                    <measurement group_id="O2" value="2.7" spread="3.1"/>
                    <measurement group_id="O3" value="0.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Carotid Intima-Medial Thickness Change From Baseline With CPAP Use Change</title>
        <description>Carotid Intima-Medial Thickness are measurements of the mean values of Intima-media thickness (IMT) of carotid arteries. Caroid Intima-Medial Thickness change is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed. The carotid intimal thickness measurement was obtained by averaging the distance between the lumen-intima interface and the media-adventitia interface obtained from 5 contiguous sites 1 mm apart.</description>
        <time_frame>Baseline to up to 12 months</time_frame>
        <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
        <group_list>
          <group group_id="O1">
            <title>No CPAP Use</title>
            <description>Intervention and control patients with none/poor CPAP use</description>
          </group>
          <group group_id="O2">
            <title>Some CPAP Use</title>
            <description>Intervention patients with some CPAP (less than 4 hours per night)</description>
          </group>
          <group group_id="O3">
            <title>Good CPAP Use</title>
            <description>Intervention patients with good CPAP use (&gt;=4 hours per night)</description>
          </group>
        </group_list>
        <measure>
          <title>Carotid Intima-Medial Thickness Change From Baseline With CPAP Use Change</title>
          <description>Carotid Intima-Medial Thickness are measurements of the mean values of Intima-media thickness (IMT) of carotid arteries. Caroid Intima-Medial Thickness change is one of the measures used to assess cardiovascular risk. To determine if CPAP use had an impact on cardiovascular risk, these measures were compared among CPAP usage groups. The change from baseline up until the final measurement (up to 12 months) was assessed. The carotid intimal thickness measurement was obtained by averaging the distance between the lumen-intima interface and the media-adventitia interface obtained from 5 contiguous sites 1 mm apart.</description>
          <population>The analysis population comprises of those with a sleep apnea diagnosis from a valid sleep study and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                    <measurement group_id="O3" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication-adjusted 24-H SBP Change From Baseline</title>
        <description>Change in medication-adjusted 24-hour SBP, which is calculated as [mean 24-hour SBP in mmHg] + [patient's DDD Ã— (8.0 mmHg), was assessed between CPAP adherence groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
        <time_frame>Baseline to up to 12 months</time_frame>
        <population>The analysis population comprises of those with a sleep apnea diagnosis and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
        <group_list>
          <group group_id="O1">
            <title>No CPAP Use</title>
            <description>Intervention and control patients with none/poor CPAP use</description>
          </group>
          <group group_id="O2">
            <title>Some CPAP Use</title>
            <description>Intervention patients with some CPAP (less than 4 hours per night)</description>
          </group>
          <group group_id="O3">
            <title>Good CPAP Use</title>
            <description>Intervention patients with good CPAP use (&gt;=4 hours per night)</description>
          </group>
        </group_list>
        <measure>
          <title>Medication-adjusted 24-H SBP Change From Baseline</title>
          <description>Change in medication-adjusted 24-hour SBP, which is calculated as [mean 24-hour SBP in mmHg] + [patient's DDD Ã— (8.0 mmHg), was assessed between CPAP adherence groups. The change from baseline up until the final measurement (up to 12 months) was assessed.</description>
          <population>The analysis population comprises of those with a sleep apnea diagnosis and is split into 3 categories of CPAP use where the treatment arms are combined.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" spread="13.9"/>
                    <measurement group_id="O2" value="5.3" spread="17.3"/>
                    <measurement group_id="O3" value="0.1" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored through the 12 month follow up period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Intervention Group</title>
          <description>This group gets unattended sleep study, auto titrating CPAP, and standard CPAP support.&#xD;
Standard CPAP Intervention</description>
        </group>
        <group group_id="E2">
          <title>Enhanced CPAP Intervention</title>
          <description>This group gets an unattended sleep study, autotitrating CPAP, and enhanced CPAP support.&#xD;
Enhanced CPAP Intervention</description>
        </group>
        <group group_id="E3">
          <title>Usual Care</title>
          <description>This group usual care after TIA/stroke and a sleep study at the end of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>acute MI</sub_title>
                <description>acute MI</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Unstable angina hospitalization</sub_title>
                <description>Unstable angina hospitalization</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Urgent coronary revascularization</sub_title>
                <description>coronary revascularization</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Recurrent Stroke</sub_title>
                <description>Recurrent stroke</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="82"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Falls</sub_title>
                <description>falls</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A study design which compares the effectiveness of a diagnostic and treatment strategy to usual care may result in an underestimate of the efficacy and potency of CPAP on our outcomes. Not all patients in the intervention strategy had sleep apnea.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Henry Klar Yaggi, MD (PI)</name_or_title>
      <organization>Yale University School of medicine</organization>
      <phone>203-785-4163</phone>
      <email>henry.yaggi@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

